|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIGX |
Gene summary for PIGX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIGX | Gene ID | 54965 |
| Gene name | phosphatidylinositol glycan anchor biosynthesis class X | |
| Gene Alias | PIG-X | |
| Cytomap | 3q29 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8TBF5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54965 | PIGX | CCI_2 | Human | Cervix | CC | 7.57e-09 | 1.13e+00 | 0.5249 |
| 54965 | PIGX | Tumor | Human | Cervix | CC | 1.16e-11 | 3.78e-01 | 0.1241 |
| 54965 | PIGX | sample3 | Human | Cervix | CC | 3.68e-09 | 3.80e-01 | 0.1387 |
| 54965 | PIGX | T3 | Human | Cervix | CC | 2.09e-12 | 3.57e-01 | 0.1389 |
| 54965 | PIGX | LZE2T | Human | Esophagus | ESCC | 8.68e-05 | 4.77e-01 | 0.082 |
| 54965 | PIGX | LZE4T | Human | Esophagus | ESCC | 5.81e-13 | 2.89e-01 | 0.0811 |
| 54965 | PIGX | LZE7T | Human | Esophagus | ESCC | 9.51e-07 | 2.64e-01 | 0.0667 |
| 54965 | PIGX | LZE8T | Human | Esophagus | ESCC | 1.00e-04 | 2.17e-01 | 0.067 |
| 54965 | PIGX | LZE20T | Human | Esophagus | ESCC | 3.12e-04 | 2.75e-01 | 0.0662 |
| 54965 | PIGX | LZE21D1 | Human | Esophagus | HGIN | 6.37e-03 | 6.41e-01 | 0.0632 |
| 54965 | PIGX | LZE22T | Human | Esophagus | ESCC | 8.01e-08 | 7.80e-01 | 0.068 |
| 54965 | PIGX | LZE24T | Human | Esophagus | ESCC | 1.12e-20 | 5.50e-01 | 0.0596 |
| 54965 | PIGX | LZE21T | Human | Esophagus | ESCC | 3.69e-08 | 6.72e-01 | 0.0655 |
| 54965 | PIGX | LZE6T | Human | Esophagus | ESCC | 9.95e-03 | 1.67e-01 | 0.0845 |
| 54965 | PIGX | P1T-E | Human | Esophagus | ESCC | 1.11e-15 | 1.29e+00 | 0.0875 |
| 54965 | PIGX | P2T-E | Human | Esophagus | ESCC | 1.16e-91 | 1.66e+00 | 0.1177 |
| 54965 | PIGX | P4T-E | Human | Esophagus | ESCC | 2.26e-53 | 1.16e+00 | 0.1323 |
| 54965 | PIGX | P5T-E | Human | Esophagus | ESCC | 3.85e-26 | 7.11e-01 | 0.1327 |
| 54965 | PIGX | P8T-E | Human | Esophagus | ESCC | 4.98e-26 | 5.41e-01 | 0.0889 |
| 54965 | PIGX | P9T-E | Human | Esophagus | ESCC | 5.82e-39 | 9.66e-01 | 0.1131 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
| GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
| GO:00064973 | Esophagus | ESCC | protein lipidation | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
| GO:00421583 | Esophagus | ESCC | lipoprotein biosynthetic process | 64/8552 | 96/18723 | 2.61e-05 | 2.20e-04 | 64 |
| GO:00065063 | Esophagus | ESCC | GPI anchor biosynthetic process | 26/8552 | 32/18723 | 3.97e-05 | 3.21e-04 | 26 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00065053 | Esophagus | ESCC | GPI anchor metabolic process | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:00066642 | Esophagus | ESCC | glycolipid metabolic process | 63/8552 | 100/18723 | 3.55e-04 | 2.06e-03 | 63 |
| GO:19035092 | Esophagus | ESCC | liposaccharide metabolic process | 63/8552 | 101/18723 | 5.25e-04 | 2.90e-03 | 63 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:0009247 | Esophagus | ESCC | glycolipid biosynthetic process | 42/8552 | 68/18723 | 5.48e-03 | 2.05e-02 | 42 |
| GO:00066611 | Esophagus | ESCC | phosphatidylinositol biosynthetic process | 73/8552 | 131/18723 | 1.31e-02 | 4.28e-02 | 73 |
| GO:0042157 | Liver | Cirrhotic | lipoprotein metabolic process | 53/4634 | 135/18723 | 1.32e-04 | 1.29e-03 | 53 |
| GO:0006643 | Liver | Cirrhotic | membrane lipid metabolic process | 69/4634 | 203/18723 | 1.89e-03 | 1.19e-02 | 69 |
| GO:0042158 | Liver | Cirrhotic | lipoprotein biosynthetic process | 36/4634 | 96/18723 | 3.69e-03 | 2.03e-02 | 36 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005632 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa0056311 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa00563 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| hsa005631 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIGX | SNV | Missense_Mutation | novel | c.763C>T | p.Leu255Phe | p.L255F | protein_coding | tolerated(0.11) | benign(0.16) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PIGX | SNV | Missense_Mutation | c.235N>G | p.Leu79Val | p.L79V | protein_coding | tolerated(0.95) | benign(0.108) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| PIGX | SNV | Missense_Mutation | c.808N>C | p.Lys270Gln | p.K270Q | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| PIGX | SNV | Missense_Mutation | novel | c.178G>T | p.Asp60Tyr | p.D60Y | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PIGX | SNV | Missense_Mutation | c.235N>A | p.Leu79Ile | p.L79I | protein_coding | deleterious(0.04) | benign(0.359) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| PIGX | SNV | Missense_Mutation | novel | c.426N>A | p.Phe142Leu | p.F142L | protein_coding | deleterious(0) | benign(0.395) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PIGX | SNV | Missense_Mutation | novel | c.452G>A | p.Arg151His | p.R151H | protein_coding | deleterious(0) | possibly_damaging(0.908) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PIGX | SNV | Missense_Mutation | c.325A>C | p.Met109Leu | p.M109L | protein_coding | tolerated(0.96) | benign(0.003) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PIGX | SNV | Missense_Mutation | novel | c.327N>T | p.Met109Ile | p.M109I | protein_coding | tolerated(0.23) | benign(0.006) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PIGX | SNV | Missense_Mutation | novel | c.430N>A | p.Ala144Thr | p.A144T | protein_coding | tolerated(0.08) | benign(0.106) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |